---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290845986.md"
description: "Mesoblast shares are trading lower. The company drew down $50 million from its five-year facility."
datetime: "2026-06-25T13:20:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290845986.md)
  - [en](https://longbridge.com/en/news/290845986.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290845986.md)
generator: "portal-rs"
---

# 

Mesoblast shares are trading lower. The company drew down $50 million from its five-year facility.

### Related Stocks

- [MSB.AU](https://longbridge.com/en/quote/MSB.AU.md)
- [MESO.US](https://longbridge.com/en/quote/MESO.US.md)

## Related News & Research

- [3 Australian Founder Led Stocks With Up To 17% Revenue Growth](https://longbridge.com/en/news/298347445.md)
- [Post-Approval Safety Risks Threaten Mesoblast’s Ryoncil Commercialization in Fragile Pediatric SR-aGVHD Market](https://longbridge.com/en/news/297478637.md)
- [Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment](https://longbridge.com/en/news/296134582.md)
- [Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline](https://longbridge.com/en/news/294369651.md)
- [Bell Potter Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)](https://longbridge.com/en/news/284855691.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**